Jagsonpal Pharmaceuticals has disclosed that its promoters and promoter group members did not create any encumbrance over the company's shares during the financial year ended March 31, 2026. The declaration, submitted to BSE and NSE, confirms that no shares were encumbered directly or indirectly by the promoters, including Infinity Holdings, Rajpal Singh Kochhar, and Aresko Progressive Private Limited. This compliance filing was made under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Promoter Disclosures

The disclosure was signed by Pratham Rawal, Company Secretary & Compliance Officer of Jagsonpal Pharmaceuticals Limited, on April 09, 2026. Infinity Holdings, a promoter entity, separately declared via Director Ahmad Tariq Hossanee on April 06, 2026, that it had not made any encumbrance of shares during the specified period. Rajpal Singh Kochhar and Aresko Progressive Private Limited also confirmed the status based on information received from other promoter group members.

Shareholding Details

The filing includes an annexure listing the members of the promoter and promoter group. The table below details the shareholding for those entities where specific share counts were disclosed.

The list of promoter group members includes numerous entities such as Aresko Life Sciences Private Limited, Sewara Buildtech Private Limited, and various LLPs and trusts, though share counts were not specified for all entries in the annexure.

Jagsonpal Pharmaceuticals has entered into a definitive agreement to acquire an 85% equity stake in Aequitas Healthcare Private Limited for a cash consideration of ₹20.8 crore. The transaction, announced on June 29, 2026, marks the company's strategic entry into the hospital segment and is aimed at gaining immediate access to institutional networks. The acquisition is expected to be completed by July 15, 2026, subject to the fulfilment of customary closing conditions.

Aequitas Healthcare, incorporated in 2017, is a Mumbai-based pharmaceutical entity engaged in the sale and distribution of products to hospitals. The target company reported a revenue from operations of ₹53.31 crore for FY 2025-26. The acquisition does not constitute a related party transaction, and no governmental or regulatory approvals are required for the deal to proceed.

Strategic Rationale and Financials

The acquisition aligns with Jagsonpal Pharmaceuticals' objective of strengthening its presence in the healthcare ecosystem by leveraging Aequitas's established relationships with leading hospital chains. Management stated that the hospital segment contributes approximately 10% of pharma industry sales and is growing faster than the retail prescription market. The transaction is intended to reduce the time required to build these relationships organically.

The deal involves the purchase of 85% of the paid-up equity share capital of Aequitas Healthcare. The current directors of the target company will retain the remaining 15% stake and continue to be associated with the business. The consideration of ₹20.8 crore will be funded from the internal accruals of Jagsonpal Pharmaceuticals.

Aequitas Healthcare Financial Performance

Aequitas Healthcare has recorded consistent revenue figures over the past three financial years. The company operates exclusively in India and focuses on the pharmaceutical and healthcare industry.

Management Commentary

Manish Gupta, Managing Director of Jagsonpal Pharmaceuticals, described the acquisition as an important strategic milestone that provides a ready platform in the hospital segment. He emphasized that the company's portfolio of established brands would benefit from Aequitas's institutional relationships. Amrut Medhekar, Chief Operating Officer, noted that the transaction transforms the company into an omnichannel specialty healthcare business.

Shailesh Kamat, Director of Aequitas Healthcare, expressed confidence that the partnership would unlock new opportunities for stakeholders and benefit the healthcare ecosystem. J Sagar & Associates acted as legal advisors to Jagsonpal Pharmaceuticals, while Noverra Partners advised Aequitas Healthcare on the transaction.